-
Mar 17, 2024 | 
ajmc.com | Laura Joszt |Justina Petrullo
Typically, patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) receive aggressive chemotherapy treatment that requires long hospital stays, but it is possible to put the foundation in place for these patients to receive support in the outpatient setting in order for them to maintain quality of life and remain close to the people who matter to them, explained Jennifer Vaughn, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital.
-
Mar 1, 2024 | 
ajmc.com | Laura Joszt |Justina Petrullo
With most patients with myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes (MDS) experiencing long-term, chronic disease, it’s important to discuss their priorities and set up the relationship with their providers upfront, explained Jennifer Vaughn, MD, assistant professor in the division of hematology at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute.
-
Oct 29, 2023 | 
centerforbiosimilars.com | Skylar Jeremias |Justina Petrullo
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, comments on concerning data from Cardinal Health and Spherix Global Insights regarding the potential growth of the US adalimumab market, including providers’ views on interchangeability and payers’ influence on utilization.
-
Oct 22, 2023 | 
centerforbiosimilars.com | Skylar Jeremias |Justina Petrullo
There are many steps that health systems can take to prevent the nocebo effect when transitioning patients from Humira (reference adalimumab) to an adalimumab biosimilar, according to Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University. TranscriptCan you discuss the importance of pharmacovigilance in populations with Crohn disease and ulcerative colitis since there haven’t been many studies evaluating adalimumab biosimilars in these patients?
-
Oct 17, 2023 | 
formularywatch.com | Justina Petrullo
No difference was found in the safety profiles or immunogenicity rates in patients who were switched and those who stayed on a reference biologic or biosimilar, according to the first systematic review using statistical methods to address switching risk in patients between reference biologics and biosimilars in PLoS One.
-
Oct 15, 2023 | 
ajmc.com | Justina Petrullo
Addressing disparities in leukemia/lymphoma care is a next step since multiple disparities have already been identified, discusses Alma Habib, MD, hematology medical oncology fellow at The Ohio State University. TranscriptHow are disparities in leukemia/lymphoma treatment being addressed in the current treatment landscape? I think over the past few years, we've really done a good job of identifying disparities in our research.
-
Oct 15, 2023 | 
centerforbiosimilars.com | Skylar Jeremias |Justina Petrullo
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, highlights the importance of his study comparing an adalimumab (Cyltezo) with the refrence product (Humira) patients with gastroenterology conditions. TranscriptWhat role can your trial play in improving patient and provider confidence in using adalimumab biosimilars for Crohn disease and ulcerative colitis?
-
Oct 14, 2023 | 
ajmc.com | Justina Petrullo |Giuliana Grossi
In an interview with The American Journal of Managed CareⓇ, Sarah Wall, MD, assistant professor in the Division of Hematology at The Ohio State University Comprehensive Cancer Center, emphasizes the need to study treatments for different age groups, particularly focusing on older adults with hematologic disorders. Even the FDA has stressed this due to disease variations and social dynamics, she explains. TranscriptWhat are some unique struggles that older adults with hematologic disorders face?
-
Oct 13, 2023 | 
centerforbiosimilars.com | Justina Petrullo
Hi, I’m Justina Petrullo for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars. Here are the top 5 biosimilar articles for the week of October 9, 2023. Number 5: Sarfaraz K. Niazi, PhD, summarized the citizen petitions he's filed to the FDA as well as changes he believes are needed to propel the biosimilar industry into the future, including calling on biosimilar manufacturers to help.
-
Oct 12, 2023 | 
ajmc.com | Justina Petrullo
Oral chemotherapy agents offer patients a reprieve from fees and facility costs, but they also put the cost of vital medications on the patient, highlighting an area of need, discusses Jennifer Vaughn, MD, assistant professor in the division of hematology at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute. TranscriptWhat strides are being made to improve and expand access to value-based care in hematology, and what more needs to be done?
